Navigation Links
Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Date:8/26/2009

MOUNTAIN VIEW, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

"We are pleased that our stockholders have overwhelmingly supported this transaction," said Thomas B. King, Alexza President and CEO. "We have reacquired full ownership of the three product candidates being developed in the Symphony Allegro partnership, and we welcome Symphony Capital Partners and their co-investors as new Alexza stockholders."

The successful stockholder vote was a condition to the completion of Alexza's previously announced option exercise to purchase all of the equity of Symphony Allegro. In June 2009, Alexza and Symphony Capital Partners announced that they had negotiated new terms to satisfy the exercise price for Alexza's option exercise to acquire Symphony Allegro. Under the terms of the Amended and Restated Purchase Option Agreement, Alexza:

  • issued 10 million shares of Alexza common stock to Symphony Capital and its co-investors,
  • issued five-year warrants for 5 million shares of Alexza common stock to Symphony Capital and its co-investors, at an exercise price of $2.26 per share (a 25% premium to the 30-day trading average closing price of the Company's common stock prior to the June announcement of the option exercise),
  • canceled previously outstanding five-year war
    '/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009
2. Alexzas Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
3. Alexzas Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
4. Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
5. Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
6. Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
7. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
8. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
9. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
10. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Md. (PRWEB) October 21, 2014 Shimadzu ... an LC/MS/MS data tool for the pain management and ... of data processing and review by allowing users to ... to clinicians. , QuantAnalytics allows analysts to filter ... This expedites data processing by eliminating the need to ...
(Date:10/22/2014)... Ras Al Khaimah, UAE (PRWEB) October 22, 2014 ... in game-changing life science and healthcare projects, announces the ... MBBS MRCGP DRCOG DCH to its advisory team. Dr. ... research advisory team. , A graduate of ... Dr. Siddiqui was subsequently degreed in medicine in 2001. ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by product ... Table-top Counters) by End-user (Inpatient Pharmacy Automation, Outpatient ... 2019” analyzes and studies the major market drivers, ... and the Rest of the World (RoW). , ... through 300 pages and in-depth TOC on "Pharmacy ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... the Supreme Court in eBay Inc. v. Mercexchange LLC, ... should be granted an injunction must be determined under ... injury; (2) inadequacy of remedies at law; (3) balancing ... rejected the Federal Circuit's approach that an injunction should ...
... of the leading Big Pharma companies of 2005. I promised you, at ... products and deals of 2005. , ,Let's get to it: , ... Disease Area Sales ($billions) ... $12.9 +6% 2. Plavix (Bristol-Myers Squibb) ...
... a developer of protein chip technologies, has received ... National Institutes of Health to develop a test that ... estimated 50 million Americans suffer from mild to chronic ... for children and senior citizens. GenTel's protein chips use ...
Cached Biology Technology:Supreme Court decision in eBay case could affect value of patents 2Big Pharma's continued hunger and search for new products 2Big Pharma's continued hunger and search for new products 3Big Pharma's continued hunger and search for new products 4GenTel gets federal grant to develop allergy test 2GenTel gets federal grant to develop allergy test 3
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... Purdue University researchers have found a genetic mutation that allows ... discovery that could reduce the amount of water required for ... conditions. Plants can naturally control the opening and closing ... water. During drought conditions, a plant might close its stomata ...
... study recently published in the journal Biology Letters ... much as bamboo forests. This work, which was ... Chinese Academy of Science, San Diego Zoo Global, China ... Sichuan Forestry Department, could assist conservationists in creating strategic ...
... RIVERSIDE, Calif. Ten researchers at the University of California, ... the Advancement of Science ( AAAS ). Including this year,s ... been recognized with AAAS Fellow distinction is 190. Election ... by their peers. This year AAAS gave this honor to ...
Cached Biology News:Gene helps plants use less water without biomass loss 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 3
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
...
Biology Products: